Paroxetine (Paxidep CR (25 mg)) is an SSRI antidepressant, prescribed for major depression, obsessive-compulsive disorder, panic disorder, social anxiety and generalized anxiety disorder.It increases ...
Mylan has launched generic versions of GlaxoSmithKline’s Paxil CR (paroxetine hydrochloride controlled-release tablets) in 12.5mg and 25mg dosage strengths. Mylan has also received the right to market ...
Paroxetine (as HCl) 12.5mg, 25mg, 37.5mg; extended-release tabs. Increased risk of suicidal thoughts and behavior in children and young adults; monitor all patients for clinical worsening or unusual ...
Lannett Company, Inc. (NYSE: LCI) revealed it received FDA approval recently for its Abbreviated New Drug Application (ANDA) for Paroxetine Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg.
TOKYO, March 30, 2012 - GlaxoSmithKline K.K. (President: Philippe Fauchet, Head Office: Shibuya-ku, Tokyo, hereinafter referred to as GSK) and Dainippon Sumitomo ...
GlaxoSmithKline has returned its antidepressant Paxil CR to the market, nearly four months after federal officials seized the drug from three factories for failing to meet manufacturing standards. The ...
A pharmaceutical product that has tentative approval cannot be marketed or sold in the US. Photo: Bloomberg New Delhi: Lupin Ltd, the country’s Mumbai-based third largest drug maker, said on Friday ...
PITTSBURGH, Oct. 23 -- Mylan Inc. today announced that it and its subsidiary Mylan Pharmaceuticals Inc. have entered into a patent license and settlement agreement with GlaxoSmithKline (GSK) relating ...
Paroxetine (Pari CR (25 mg)) is an SSRI antidepressant, prescribed for major depression, obsessive-compulsive disorder, panic disorder, social anxiety and generalized anxiety disorder.It increases the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results